Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
358actual
Sites
28
Countries
France, South Korea, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2014-10-31 | actual | When the study began enrolling |
| Primary completion | 2025-03-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2014-10-15 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions
- Drug: Administration of ceralasertib
- Drug: Administration of ceralasertib in combination with olaparib
- Drug: Administation of ceralasertib in combination with durvalumab
- Drug: Administration of ceralasertib monotherapy
- Drug: Administration of ceralasertib and olaparib
- Drug: Administration of ceralasertib and durvalumab
- Drug: Administration of ceralasertib in combination with AZD5305
- Drug: Administration of ceralasertib in combination with carboplatin
Primary outcomes
what the primary-completion date above is the date OFThe number of subjects with adverse events/serious adverse events
measured From baseline until 28 days after discontinuation of study treatment for Module 1, 2 and 5 or until 90 days after discontinuation of study treatment for Module 3 and 4
Module 4 only: Effect of food on ceralasertib absorption by Intensive PK assessments after a single oral dose of ceralasertib (Part A)
measured From 0h to 24h on Day 2 and Day15 in Cycle 0 (Part A) - Cycle 0 is 15 days
Module 4 only: Effect of ceralasertib on ECG parameters (HR, PR, QRS and QTcF) by ECG recordings
measured From 0h to 24h on Day 2, Day 8 and Day15 in Cycle 0 (Part A) - Cycle 0 is 15 days
Publications
- PMID 41917211 — linked by the registry
- PMID 34904813 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed